QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOP...

 myriad-genetics-publishes-meta-analysis-of-3532-mdd-patients-showing-genesight-psychotropic-test-improves-response-and-remission-rates-vs-standard-treatment

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publ...

Core News & Articles

Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tis...

 stock-market-today-us-futures-edge-higher-as-investors-await-earnings-from-mcdonalds-uber-and-walt-disney

US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down ...

 myriad-genetics-surges-3567-after-hours-following-strong-q2-earnings-beat-raised-revenue-guidance

After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped ...

 myriad-genetics-affirms-fy2025-adj-eps-guidance-of-002-002-vs-001-est-raises-fy2025-sales-guidance-from-80700m-82300m-to-81800m-82800m-vs-81040m-est

Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs $(0.01) analyst estimate. ...

 myriad-genetics-q2-adj-eps-005-beats-001-estimate-sales-21310m-beat-20188m-estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.0...

 earnings-preview-myriad-genetics
Earnings Preview: Myriad Genetics
08/04/2025 20:08:20

 myriad-genetics-announces-monstar-screen-3-data-advancing-pan-cancer-mrd-testing

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new mole...

 scotiabank-downgrades-myriad-genetics-to-sector-perform-lowers-price-target-to-6

Scotiabank analyst Sung Ji Nam downgrades Myriad Genetics (NASDAQ:MYGN) from Sector Outperform to Sector Perform and lowers ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION